This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (11)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

The Metoprolol Atherosclerosis Prevention in Hypertensives Trial

MARVIN MOSER, MD; SHELDON SHEPS, MD

Arch Intern Med. 1989;149(10):2174-2175.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Physicians have come to depend on the results of long-term clinical trials to make treatment decisions. This is true for trials that consider, for example, the management of diabetes, coronary heart disease, hypertension, and malignant diseases.

The recently published Metoprolol Atherosclerosis Prevention in Hypertensives (MAPHY) study,¹ which compared the results of a β-blocker, metoprolol, with a diuretic treatment group in moderately severe, middle-aged male hypertensive subjects in 66 centers from 11 countries, presents confusing results with differing interpretations. These should be clarified as quickly as possible before claims resulting from this trial are widely disseminated. This study compared the effects of metoprolol, a selective β-adrenergic inhibiting agent, in 1609 white men (aged 40 to 64 years) with pretreatment diastolic blood pressures between 100 and 130 mm Hg, with those of a thiazide diuretic (hydrochlorothiazide or bendroflumethiazide) in 1625 patients. Mean age was 52 years in each group and serum lipid . . . [Full Text PDF of this Article]

Author Affiliations
Science Base Committee of the National High Blood Pressure Coordinating Committee National Heart, Lung, and Blood Institute Bethesda, MD 20814

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?